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ABSTRACT 
Objective: To synthesize, evaluate and performing the docking studies of novel formazan derivatives as enoyl-ACP reductase inhibitors. 
Materials: In the present investigation, a series of formazans (Ia-d) were synthesized by stirring aryl diazonium salts solution with Schiff's base at 
0-5˚C for 2 h. The intermediate azomethine (Schiff base) itself was synthesized by condensation of para aminobenzoic acid with dimethylamino 
benzaldehyde in presence of a glacial acetic acid as a catalyst. The antimicrobial activity was done for these synthesized compounds by cup plate 
method. Moreover, the antimicrobial activity was further confirmed by its molecular docking approach study by using Molecular Operating 
Environment (MOE) 2009.10 software. 
Results: In the present study all the synthesized compounds (Ia-Id) showed the enhanced zone of inhibition against S. aureus, B. subtilis, E. coli and 
S. typhi (5±0.12 to 12±0.45) whereas, the antifungal activity against A. niger and C. albicans were showed the zone of inhibition in the range of 
9±0.51 to 12±0.43 when compared to that of the standard drug.  
Further the docking study reveals that, only three of the formazan compounds under observation (Ia, Ib and Ic) have higher binding affinity with the 
receptors enzymes enoyl-ACP reductase
Conclusion: Therefore our present report shows that formazans could be the potential drug candidate that inhibits the microbial activity by 
interacting and inhibiting the enoyl-ACP reductase enzyme which is confirmed by its both in vitro antimicrobial study and as well as from its 
docking study. 
, which is in the narrow range of binding energy for the protein PDB: 1C14 is-24.4598 to-23.9377 kcal/mol, 
which shows the further confirmation of these formazan compounds as better microbial inhibitor.  
Keywords: Formazans, Schiff base, Enoyl-ACP Reductase, Docking, MOE 




Large use of antibiotics against pathogenic microorganism has a 
lot of toxic and side effects. Owing to this, a potential research in 
search of alternative options is required to combat with the 
resistance of bacteria [1]. There are numerous antibiotics have 
been produced, but the clinical efficacy of these existing antibiotics 
is being threatened by the emergence of multidrug-resistant 
pathogens [2]. In the search for safer and more potent therapeutic 
agents, a popular approach is synthesis and evolution of 
biologically active compounds. Azomethine derivatives have been 
prominent research subject because of their pharmacological 
characteristics and complexometric behaviour. Azomethine 
derivatives play a pivotal role in displaying various biological 
activities viz. anticancer, antitubercular, anti-HIV, antioxidant and 
antimicrobial. Azomethines are the important intermediate for the 
synthesis of derivatives such as pyrazolines, isoxazolines, 
azetidinones, thiazolidinones and formazans. 
Formazans compounds have the general structure with an 
azohydrazon arrangement of functional groups. Independently 
Bamberger and Von Pechman synthesized the first formazan 
afterwards there have been numerous formazans synthesized and 
investigated. Formazans are coloured compounds ranging from 
cherry red to a deep purplish black and contain atoms of (-N=N-C=N-
NH-) because of their π→π* transitions of π -electrons. Formazans 
are generally solids of relatively low melting point compound with 
huge the size of its structure [3]. Formazans have been studied 
widely owing to their ready ease of access, assorted chemical 
reactivity and its biological activities [4, 5]. Formazans have 
attracted attention because of their diverse medicinal applications 
such as antimicrobial [6-15], (including antiviral, antifungal, 
antibacterial), antifertility [16], analgesic and anti-inflammatory 
[17-20], antitubercular [21, 22], anticonvulsant [23, 24], 
antiparkinsonian [25, 26], anticancer, anti HIV [27-29], 
antiproliferative [30, 31] and antihyperglycemic [32] activities.  
Owing to the universal impact of these devastating diseases, there is 
an urgent need for the development of new derivatives with 
promising antimicrobial activities. Several different approaches such 
as targeting bacterial virulence, high-throughput screening (HTS), 
structure-based drug discovery (SBDD), chemical modifications of 
the known drugs and combinatorial chemistry have been discovered 
to search novel biologically important lead [33-35]. Apart from this, 
now a day, the new concept of computer-aided drug design (CADD) 
and docking has revolutionized the entire drug discovery and 
development program.  
Formazan derivatives were known to possess various 
pharmacological activities. Hence it was decided to synthesize 
new derivatives of formazan by coupling reaction. The goal of 
the present study is to synthesis compounds with greater 
efficacy, safety and less toxic for the use of medicinal purpose. In 
the light of these observations and diverse literature survey, our 
attention was drawn towards to synthesis and study of few 
newer formazan derivatives and was evaluated for antimicrobial 
activities.  
In support with this in vitro antimicrobial activity result and by 
taking into consideration of NADH-dependent enoyl-Acyl Carrier 
Protein reductase (enoyl-ACP reductase) as the target receptor of 
the antimicrobial activity [36], it was focused to perform the 
molecular docking studies and screening for supportive information 
between in silico studies with the in vitro results. Docking studies 
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with newly synthesized compounds were performed to determine 
the best in silico conformation. Due to this, an attempt was made in 
the present research to design, synthesis and docking studies of 
novel formazans derivatives as an anti-E. Coli mediator having 
enoyl-ACP reductase inhibitor.  
MATERIALS AND METHODS 
The chemicals used of AR and LR grade and were obtained from 
Merck, Hi-Media and Sigma-Aldrich, SD Fine chem., Mumbai. All the 
chemicals were used as received without further purification.  
Experimental section  
Melting points were determined in open capillaries on a Thomas 
Hoover apparatus and are uncorrected. The synthesized compounds 
were characterized by the following methods. IR spectra of 
synthesized compounds were recorded on a Schimadzu Fourier 
Transform Infrared Spectrophotometer in the range of 4000 cm-1–
400 cm-1
General procedure for synthesis of new formazan derivatives  
 using KBr pellet technique. Proton NMR Spectra were 
recorded using BRUKER Advance 500MHz NMR Spectrometer using 
the solvent deuterated chloroform. Chemical shifts were recorded in 
parts per million and Trimethylsilane as an internal standard.  
Synthesis of new formazans involved two steps. In the first step, 
azomethine was synthesized by the reaction of a para-aminobenzoic 
acid and dimethylamino benzaldehyde in presence of an acidic 
catalyst glacial acetic acid. In second step formazans were 
synthesized from azomethine (Schiff base) by reaction with various 
aryl diazonium salt at 0-5 °C in the presence of pyridine. 
Synthetic procedure 
Step 1: Synthesis of 4-{[4-(dimethylamino) benzylidene] amino} 
benzoic acid (I) 
0.02 mol of para-aminobenzoic acid and 0.02 mol of para 
dimethylamino benzaldehyde were dissolved in 30 ml of ethanol. 
Then few drops of glacial acetic acid were added to it and the 
contents were refluxed for 1h. The reaction mixture was cooled 
and poured into water. The yellow colour solid product was 
separated. This was filtered, washed with water, dried and 
recrystallized from ethanol. Formation and purity of products 
were checked by thin layer chromatography using chloroform, 
methanol as mobile phase and silica gel G as the stationary phase 
and the spots were visualized by iodine vapour. 
Step 2: Synthesis of Aryl diazenyl (dimethyl aminophenyl) 
methylidene aminobenzoic acid derivatives [I(a-d)] 
0.006 mol of different aromatic amines dissolved in 15 ml of 2 M 
hydrochloric acid. The contents were cooled to 0-5 °C in an ice bath. 
The cold solution of sodium nitrite (0.012 mol in 10 ml water) was 
slowly added to the amine solution with stirring and maintain the 
temperature at about 0-5 °C. 
0.004 mol of product (I) obtained in step 1 was dissolved in 10 ml of 
pyridine and the mixture was cooled in an ice bath at 0-5 °C. To this 
mixture, the cold diazotized solution was added dropwise with 
stirring and stirring was continued for 2h. The reaction mixture kept 
in an ice bath for further 3h. The coloured solid product was 
separated and it was filtered, washed with a minimum quantity of 
water, dried and recrystallized from ethanol. The overall synthetic 
scheme represented as fig. 1. 
Antimicrobial activity 
Antifungal activity and antibacterial activity 
The newly synthesized compounds were subjected for antifungal 
activity [10, 14] against fungi such as A. niger (ATCC 16404) and C. 
albicans (ATCC 18804), and antibacterial activity [10, 14] against 
gram-positive bacteria such as S. aureus (MTCC 1133) and B. subtilis 
(MTCC 7443) and gram-negative bacteria such as E. coli (MTCC 1692) 
and S. typhi (ATCC 19430). All the bacterial and fungal strains were 
purchased from VNS enviro biotech pvt ltd., Chennai, Tamilnadu. The 



































Fig. 1: Synthetic scheme 
 
Molecular docking studies 
Preparation of ligand files 
The ligand files for the molecular docking studies were prepared in 
the Molecular Operating Environment (MOE, 2009.10) by Chemical 
Computing Group (CCG). The molecular geometries were drawn, 
correct 3D structures were ensured and were followed by energy 
optimization at a standard MMFF94 force field level, with a 0.0001 
kcal/mol energy gradient convergence criterion [37]. The module 
builder of MOE program was used for this purpose and after 
building the molecule it was saved as a molecular database (.mdb) 
file for further studies. 
Preparation of receptor 
The first step of the protein preparation involved removal of water 
and hetero molecule by using sequence editor (SEQ) window which 
is default in MOE programme. Further, the energy was minimized 
followed by active site prediction. The crystal 3D structure of 
enzymes enoyl-ACP reductase (PDB: 1C14), was obtained from 
Thangavelu et al. 
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Protein Data Bank (http://www.rcsb.org/pdb). The pdb file was 
imported to MOE suite where receptor preparation module was 
used to prepare the protein. All the bound water molecules were 
removed from the complex. Both polar and non-polar hydrogens 
were added and 3D structure was corrected. The 3-D protonated 
structure was energy minimized. Since the protein was devoid of 
associated ligand, so the pocket was identified using the active site 
finder module of the MOE. In order to visualize the binding pocket, 
alpha spheres were created followed by the generation of dummy 
atoms on the centres of these spheres. 
RESULTS AND DISCUSSION 
The pockets were found to be 
deep small gorges lined with the key residues including both 
hydrophobic and hydrophilic amino acids.  
Docking methodology  
The optimized ligands were docked with the enzymes enoyl-ACP 
reductase (PDB: 1C14) using the MOE-Dock program. For docking 
simulations, the placement was set as triangular matcher, rescoring 
was set as London dG, the number of retaining was set as 10 and the 
refinement was set as forcefield on MOE docking and was utilized to 
generate 10 poses of each compound. As a result of the docking run, 
the .mdb output files were created with scoring and multiple 
conformations of each compound. All the docked conformations 
were analyzed and the best-scored pose for each compound was 
selected for further interaction studies.  
The target compounds were synthesized by coupling reaction of Schiff’s 
base and various aryl diazonium salts. The synthesized compounds were 
obtained in moderate yield. The percentage yield and melting point of 
the synthesized compounds were recorded and presented uncorrected. 
Thin layer chromatography was performed for the synthesized 
compounds. The only single spot was obtained on silica gel G plate as a 
stationary phase and chloroform, ethanol as a solvent system. This 
showed that the compounds were obtained in a pure state. IR and 1
Compound Ia: 4-({[4-sulphamoyl phenyl) diazenyl] [4-(dimethyl 
amino) phenyl] methylidene} amino) benzoic acid. Yield 67%. m. p. 
164 ° C. IR γ (cm
H 
NMR Spectral data of synthesized compounds were given below. 
-1) (KBr): 3306-primary sulphonamide–NH stretch, 
3182-3076 (OH stretch-COOH), 3026-CH stretch of aromatic, 2999-
2991-CH stretch of methyl, 1672-C=O-stretch of–COOH, 1606-C=N 
stretch, 1591and1521–C=C stretch of aromatic, 1425-N=N-stretch, 
1178-=S=O-stretch. 1H NMR δ ppm (TMS): 0.9-1.3–6H (CH3), 3.3-
3.8–2H (SO2NH2
Compound Ib: 4-({[4-sulphophenyl) diazenyl] [4-(dimethylamino) 
phenyl] methylidene} amino) benzoic acid. Yield 72%. m. p. 228 ° C. 
IR γ (cm
), 8-8.5–12 H. 
-1) (KBr): 3308-OH stretch of SO3H, 3182-OH stretch of–
COOH, 3030-CH stretch aromatic, a 2991-CH stretch of CH3, 1670-
C=O stretch of–COOH, 1606-C=N stretch, 1591 and a 1521-C=C 
stretch of aromatic, 1425-N=N stretch. 1H NMR δ ppm (TMS): 0.9-
1.4–6H (CH3), 2.3–1H (SO3
Compound Ic: 4-({[2-chlorophenyl) diazenyl] [4-(dimethyl amino) 
phenyl] methylidene} amino) benzoic acid. Yield 68%. m. p. 148 ° C. 
IR γ (cm
H), 7.4-7.9–12H. 
-1) (KBr): 3201-OH stretch COOH, 3082-CH stretch aromatic, 
2995-CH stretch CH3, 1718 and 1683-C=O stretch COOH, 1602,-C=N 
stretch 1502,-C=C stretch, 1442-N=N stretch. 1H NMR δ ppm (TMS): 
1.0-2.9–6H (CH3
Compound Id: 4-({[(1-naphthyl) diazenyl] [4-(dimethylamino) 
phenyl] methylidene} amino) benzoic acid. Yield 56%. m. p. 189 ° C. 
IR γ (cm
), 6.7–6.9–4H (Ar H), 7-7.5–4H (ArH), 7.9-8.2–4H 
(ArH). 
-1) (KBr): 3113-OH stretch-COOH, 2987-CH stretch aromatic, 
2949-CH stretch CH3, 1681-C=O stretch–COOH, 1599-C=N stretch, 
1548 and 1525-C=C-stretch aromatic, 1435-N=N-stretch. 1H NMR δ 
ppm (TMS): 1.3–3H (CH3), 3.2–3H (CH3
Antimicrobial activity 
), 6.7–9.8–15 H (ArH). 
Formazans have been reported to possess an attractive 
antimicrobial activity [6-15]. Further to confirm this, the zone of 
inhibition value of the all the synthesized compounds (Ia-Id) were 
showed good antifungal and antibacterial activity when compared to 
that of the standard drug. The activity may be due to the presence of 
electron withdrawing groups (-SO2NH2,-SO3
 
H,-Cl) in synthesized 
formazan compounds Ia–Id. The results were summarized in table 1 
and 2 respectively. 
Table 1: Antifungal activity (zone of inhibition in mm) of the synthesized compounds 
Compound Aspergillus niger Candida albicans 
Concentration (µg/ml) Concentration (µg/ml) 
 500 800 1250 2000 500 800 1250 2000 
Ia - - 9±0.51 10±0.35 - - 7±0.31 - 
Ib - - 12±0.43 9±0.31 - - 6±0.33 7±0.26 
Ic - - 10±0.35 9±0.41 - - 12±0.54 11±0.40 
Id - - - 8±0.52 - - - 7±0.13 
Standard (250µg/ml) (Griseofulvin) 28±0.46 24±0.22 
Values are mean of triplicate readings (mean±SD); (-) indicates no zone of inhibition 
 
Table 2: Antibacterial activity (zone of inhibition in mm) of synthesized compounds 
Compound Gram positive bacteria Gram negative bacteria 
S. aureus B. subtilis E. coli S. typhi 
Concentration (µg/ml) Concentration (µg/ml) 
 250 1250 250 1250 250 1250 250 1250 
Ia 7±0.36 8±0.43 - - - - - 6±0.13 
Ib 6±0.32 7±0.40 - - 7±0.22 8±0.51 6±0.21 9±0.43 
Ic 7±0.12 8±0.31 8±0.41 12±0.65 14±0.65 11±0.53 7±.26 12±0.45 
Id 5±0.12 6±0.32 8±0.56 11±0.38 - - - - 
Standard (250µg/ml) (Gentamycin) 18±0.56 17±0.35 15±0.53 14±0.54 
Values are mean of triplicate readings (mean±SD); (-) indicates no zone of inhibition 
 
Molecular docking study of the synthesized formazans 
In the present study, the docking of novel formazan derivatives as an 
anti-E. Coli mediator having enoyl-ACP reductase inhibitor was 
performed. Enoyl-acyl carrier protein reductase is a fatty acid 
synthase II enzyme involved in the bacterial fatty acid biosynthetic 
pathway of the bacteria. This enzyme also involved in fatty acid 
elongation in the cell wall synthesis of bacteria [36]. 
From the docking result, it was observed that the docked 
conformations for each compound were analyzed and it was found 
that the most favourable docking poses with a maximum number of 
Thangavelu et al. 
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interactions were those which were ranked the highest based on the 
minimal binding energy, which was computed as a negative value by 
the software. The most favourable docking poses of the 10 docked 
conformations for each compound were analyzed to further 
investigate the interactions of the docked conformations within the 
active sites. The tremendous number of interactions with active site 
residues coupled with favourable binding energy proclaim that these 
compounds may serve as an effective replacement for the 
antimicrobial agents. 
  
These ligands showed a proper binding pattern 
and anchored tightly inside the active site gorge (Site I) of the 
protein. The 2D ligand-protein interactions were visualized using 
the MOE ligand interaction program and recorded in table 3. 
Table 3: Docking results for formazans derivatives with protein PDB: 1C14 
Compound no S rmsd_refine E_conf E_place E_score1 E_refine No. of conf. 
Ia -24.4598 3.8591 -16.2233 -103.6424 -12.3635 -24.4598 10 
Ib -24.8136 3.0560 30.4684 -94.1171 -13.6685 -24.8136 10 
Ic -23.9377 1.6005 87.5645 -107.4476 -11.6685 -23.9377 10 
Id - - - - - - - 
S-The final score, rmsd_refine-The root mean square deviation between the pose before refinement and the pose after refinement, E_conf-The 
energy of the conformer. E_place-Score from the placement stage, E_score1-Score from the rescoring stage(s), E_refine-Score from the refinement 
stage and No. of conf-number of conformations generated by ligand. 
 
The best docking poses of all 4 selected compounds produce 
results in which Ia, Ib and Ic form a single cluster inside the active 
site cleft of the receptor as shown in fig. 2, 3 and 4. The 
compounds under observation have a higher binding affinity with 
the receptors, in the narrow range of binding energy for the 
protein 1C14 is-24.4598 to-23.9377 kcal/mol: London dG is-
13.6685 to-11.6685 
 
kcal/mol. Whereas, the compound Id was not 
shown any binding score with this protein. This was further 
confirmed by its in vitro antimicrobial activity data which is 
present in table 1 and table 2. 
 
 
Fig. 2: Ligand receptor interaction and binding surface of compound Ia with 1C14 
  
 
Fig. 3: Ligand-receptor interaction and binding surface of compound Ib with 1C14 
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Fig. 4: Ligand receptor interaction and binding surface of compound Ic with 1C14 
 
 
Docking analysis revealed that the compound Ia interacted with 
receptor through arene-arene interactions on Phe 94, and also there 
is a side chain acceptor on carbonyl group of acid moiety ser 16, 
while in Ib there is a side chain acceptor on carbonyl center of acid 
moiety at Gln 40, whereas compound Ic interacted with receptor Tyr 
146 through arene-arene interactions and there is a backbone on 
carbonyl group of acid moiety at Gly 190, (fig. 2, 3 and 4). The 
number of conformations generated by compound Ia, Ib and Ic were 
10 which indicated that flexibility is an important parameter for the 
ligand to docked deeply within the binding pocket of enoyl ACP 
reductase enzyme. The energy of confirmation for compound Ia is-
16. 2233, Ib is 30.4684 and Ic is 87.5645, which indicate compound 
is active at this energy of confirmation. Further, a careful inspection 
of the binding pocket indicated that compounds Ia, Ib and Ic adopted 
a position in a hydrophobic cage surrounded by Tyr 39, Ala 15, Leu 
195, Asp 64, Cys 63, Phe 94, Ser 16 and etc.  
CONCLUSION 
In the present study, the zone of inhibition value of the all the 
synthesized compounds (Ia-Id) was showed good antifungal and 
antibacterial activity when compared to that of the standard. The 
activity may be due to the presence of electron withdrawing groups 
(-SO2NH2,-SO3H,-Cl) of synthesized compounds Ia–Id. Further, the 
docking study reveals that, the only three compounds under 
observation (Ia, Ib and Ic) have a higher binding affinity with the 
receptors enzymes enoyl-ACP reductase
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